Draft Guidance on Efavirenz, Emtricitabine, and Tenofovir Disoproxil Fumarate

Contains Nonbinding Recommendations

This draft guidance, once finalized, will represent the Food and Drug Administration's (FDA's) current thinking on this topic. It does not create or confer any rights for or on any person and does not operate to bind FDA or the public. You can use an alternative approach if the approach satisfies the requirements of the applicable statutes and regulations. If you want to discuss an alternative approach, contact the Office of Generic Drugs.

Active ingredient: Efavirenz; Emtricitabine; Tenofovir Disoproxil Fumarate

Form/Route: Tablets/Oral

Recommended studies: 1 study

Type of study: Fasting
Design: Single-dose, two-treatment, two-period crossover in-vivo
Strength: 600 mg/200 mg/300 mg
Subjects: Normal healthy males and females, general population.
Additional Comments: Females should not be pregnant or lactating, and if applicable, should practice abstention or contraception during the study.

Analytes to measure (in appropriate biological fluid): Efavirenz, emtricitabine, and tenofovir in plasma.

Bioequivalence based on (90% CI): Efavirenz, emtricitabine, and tenofovir

Waiver request of in-vivo testing: Not Applicable

Dissolution test method and sampling times:

Please note that a Dissolution Methods Database is available to the public at the OGD website at http://www.fda.gov/cder/ogd/index.htm. Please find the dissolution information for this product at this website. Please conduct comparative dissolution testing on 12 dosage units each of all strengths of the test and reference products. Specifications will be determined upon review of the application.

Recommended Oct 2008